^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
Published date:
11/29/2018
Excerpt:
By univariate analysis (UVA) improved ORR was seen in pts with pretherapy BM blast <20%, circulating WBC <=10,000/mL, ASXL1 mutation....AZA+Nivo was effective in pts with AML...
Secondary therapy:
irinotecan
DOI:
10.1182/blood-2018-99-120157
